Wells Fargo
SABS icon

Wells Fargo’s SAB Biotherapeutics SABS Stock Holding History

Wells Fargo’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-61
Closed -$277 – 7382
2024
Q1 		$277 Buy
61
+32
+110% +$176 ﹤0.01% 6419
2023
Q4 		$202 Buy
29
+2
+7% +$17 ﹤0.01% 6610
2023
Q3 		$169 Buy
27
+2
+8% +$15 ﹤0.01% 6628
2023
Q2 		$205 Buy
25
+6
+32% +$49 ﹤0.01% 6694
2023
Q1 		$82 Hold
19
– – ﹤0.01% 6979
2022
Q4 		$109 Buy
19
+1
+6% +$9 ﹤0.01% 6771
2022
Q3 		$0 Buy
18
+1
+6% +$10 ﹤0.01% 7255
2022
Q2 		$0 Buy
+17
New +$357 ﹤0.01% 7384

Other funds holding SABS

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
FPB
First PREMIER Bank Sioux Falls, South Dakota $619M AUM 20.21% 1-Year Est. Return

Wells Fargo's SABS Position: Q2 2024 in Review

Wells Fargo sold out of SAB Biotherapeutics (SABS) in Q2 2024, closing a stake of 61 shares — an estimated $277 sold.

Wells Fargo first reported a position in SABS in Q2 2022 and held it in 8 quarters. The position peaked at $277 in Q1 2024. 22 funds tracked by Wall St. Rank hold SABS as of Q2 2024.

  • Wells Fargo reported no remaining SAB Biotherapeutics position as of Q2 2024 after selling out during the quarter.
  • Wells Fargo sold 61 SAB Biotherapeutics shares in Q2 2024, an estimated $277.
  • Wells Fargo first reported a position in SAB Biotherapeutics in Q2 2022 and held it in 8 quarters.
  • Wells Fargo's SAB Biotherapeutics position peaked at $277 in Q1 2024.
  • 22 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q2 2024.

Based on Wells Fargo's 13F filing for Q2 2024, filed 13 Aug 2024.